Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors

BackgroundMolecular profiling of advanced EGFR mutated NSCLC has recently demonstrated the co-existence of multiple genetic alterations. Specifically, co-existing KRAS-mutations in EGFR NSCLCs have been described, despite their prevalence at progression and their role in the response to EGFR tyrosin...

Full description

Bibliographic Details
Main Authors: Giorgia Nardo, Jessica Carlet, Ludovica Marra, Laura Bonanno, Alice Boscolo, Alessandro Dal Maso, Andrea Boscolo Bragadin, Stefano Indraccolo, Elisabetta Zulato
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Oncology
Subjects:
KRAS
EGFR
liquid biopsy
non-small-cell lung cancer
cell free DNA
tyrosine kinase inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.607840/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.607840/full

Similar Items